Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

Symbio Pharmaceuticals / Equity Bottom-Up

<ul><li>Sales decreased by 56.1% YoY to JPY2.5bn, with a gross profit of JPY1.9bn and a gross margin of 76.4%.</li><li>Operating loss increased to JPY3.9bn in FY12/24, with SG&A expenses at JPY5.8bn, including R&D expenses of JPY3.4bn.</li><li>FY12/25 forecast: Sales at JPY1.9bn, operating loss at JPY4.3bn, with total SG&A expenses projected at JPY5.6bn.</li></ul>

Sales decreased by 56.1% YoY to JPY2.5bn, with a gross profit of JPY1.9bn and a gross margin of 76.4%.Operating loss increased to JPY3.9bn in FY12/24, with SG&A expenses at JPY5.8bn, including R&D expenses of JPY3.4bn.FY12/25 forecast: Sales at JPY1.9bn, operating loss at JPY4.3bn, with total SG&A expenses projected at JPY5.6bn.

Symbio Pharmaceuticals (4582 JP): Full-year FY12/24 flash update